SeriACL™ Device Trial for Anterior Cruciate Ligament (ACL) Reconstruction

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by Serica Technologies, Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Serica Technologies, Inc.
ClinicalTrials.gov Identifier:
NCT00490594
First received: June 20, 2007
Last updated: October 17, 2008
Last verified: October 2008
  Purpose

The SeriACL device was developed as an alternative to an autograft (i.e., tissue that is taken from a patient's own body) or an allograft (i.e., tissue that is taken from a cadaver) for ACL reconstruction. The SeriACL device is made of silk yarns, knit and processed with SeriCoat™ surface treatment which makes it easier to wet the material. The SeriACL device is designed to be a temporary support structure to replace the torn ACL and to stabilize the knee joint following surgical repair. It is designed to use the body's own healing process to regenerate the patient's own new ligament tissue. As the new tissue grows and the support structure is needed less over time, the SeriACL device is bioresorbed (i.e., broken down) by the patient's body. The SeriACL device is designed to be installed with standard surgical techniques for ACL repair.

This study is designed to test the safety of the SeriACL device in primary total ACL repair in patients with a torn ACL. The study will evaluate whether repair of the ACL with the SeriACL device will return the knee to normal function and what, if any, side effects will occur.


Condition Intervention Phase
Anterior Cruciate Ligament
Knee Injuries
Device: ACL Reconstruction (SeriACL™ Device)
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Center Open Study to Evaluate the SeriACL™ Device for Primary Anterior Cruciate Ligament Repair

Resource links provided by NLM:


Further study details as provided by Serica Technologies, Inc.:

Primary Outcome Measures:
  • Safety - measured by device related SAEs [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • KT-1000 Arthrometer [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Knee Surveys [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Return to Work [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: June 2007
Estimated Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: ACL Reconstruction (SeriACL™ Device)
    Bioresorbable ACL
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Complete ACL rupture
  • Injured knee range of motion >= 75% of contralateral knee
  • MCL tear grading <= 2
  • Sign informed consent.

Exclusion criteria:

  • Prior ACL reconstruction
  • Complete PCL tear
  • Locked bucket handle tear or complex tears of the menisci.
  • Contralateral knee ligament injury
  • Known joint disease
  • Known allergy to silk
  • Active drug or alcohol abuse
  • Pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00490594

Locations
Germany
Atos Clinic
Heidelberg, Germany
Heidelberg University
Heidelberg, Germany
Norway
Ullevaal Hospital
Oslo, Norway
Sponsors and Collaborators
Serica Technologies, Inc.
Investigators
Principal Investigator: Lars Engebretsen, MD Ullevaal Hospital
Principal Investigator: Hans Paessler, MD ATOS Clinic, Heidelberg
Principal Investigator: Holger Schmitt, MD Heidelberg University
  More Information

No publications provided

Responsible Party: Rebecca Horan, Serica Technologies, Inc.
ClinicalTrials.gov Identifier: NCT00490594     History of Changes
Other Study ID Numbers: CLN-ACL1
Study First Received: June 20, 2007
Last Updated: October 17, 2008
Health Authority: Germany: Ethics Commission

Keywords provided by Serica Technologies, Inc.:
ACL
ligament
ACL injury

Additional relevant MeSH terms:
Knee Injuries
Wounds and Injuries
Leg Injuries

ClinicalTrials.gov processed this record on August 27, 2014